Loading…
Inovio Pharmaceuticals, Inc. is projected to rise to $1.39 by 2027, a +18% move from its current price of $1.18. INO is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $1.15 | $1.18 | $1.21 | -0.02% |
| Jul 13 | $1.13 | $1.18 | $1.23 | -0.03% |
| Jul 14 | $1.12 | $1.18 | $1.24 | -0.05% |
| Jul 15 | $1.12 | $1.18 | $1.25 | -0.07% |
| Jul 16 | $1.11 | $1.18 | $1.25 | -0.08% |
| Jul 17 | $1.10 | $1.18 | $1.26 | -0.10% |
| Jul 18 | $1.09 | $1.18 | $1.27 | -0.12% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.09 | $1.18 | $1.27 | -0.12% |
| Week 2 | $1.06 | $1.18 | $1.31 | -0.24% |
| Week 3 | $1.03 | $1.18 | $1.34 | -0.35% |
| Week 4 | $1.01 | $1.17 | $1.36 | -0.47% |
| Week 5 | $0.9946 | $1.17 | $1.38 | -0.59% |
| Week 6 | $0.9779 | $1.17 | $1.40 | -0.70% |
| Week 7 | $0.9627 | $1.17 | $1.42 | -0.82% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon to engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
The company's lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions; INO-3112 for the treatment of HPV-related Oropharyngeal squamous cell carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 2/3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. The company's partners and collaborators ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency, HIV Vaccines Trial Network, Kaneka Eurogentec, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, and The Wistar Institute.
The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
Inovio Pharmaceuticals, Inc. (INO) is a healthcare stock in the biotechnology space. It is currently priced at $1.19 with a market capitalization of $97.91M and ranks 4242 by market cap. The stock operates within the Healthcare category and carries a controlled, smaller-cap profile relative to larger biotechs.
A major floor 19.8% below — a decisive break under it would weaken the trend.
The nearest floor, 9.3% below — buyers have tended to step in here.
The nearest ceiling, 11.0% above — a clean break opens room to run.
A major ceiling 47.5% above — clearing it would confirm fresh momentum.
Key INO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of INO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.19 | Sell | $1.19 | Sell |
| MA 10 | $1.17 | Buy | $1.17 | Buy |
| MA 20 | $1.14 | Buy | $1.16 | Buy |
| MA 50 | $1.20 | Sell | $1.21 | Sell |
| MA 100 | $1.34 | Sell | $1.34 | Sell |
| MA 200 | $1.69 | Sell | $1.64 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.80 | Neutral |
| Stoch RSI (14) | 67.32 | Neutral |
| CCI (20) | 71.49 | Neutral |
| Williams %R (14) | -28.57 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 4.42 | Buy |
| Bollinger %B (20,2) | 0.74 | Neutral |
| Stochastic %K (14) | 71.43 | Neutral |
| TRIX (15) | -0.16 | Sell |
| Awesome (5,34) | 0.02 | Buy |
| Ultimate (7,14,28) | 59.70 | Neutral |
| Momentum (10) | 0.10 | Buy |
| Aroon Osc (25) | 72.00 | Buy |
| Hull MA (9) | 1.21 | Sell |
| ADX (14) | 13.57 | Neutral |
| ATR (14) | 0.03 | Info |
The near-term technical backdrop is Neutral, with RSI14 at 60. The 50-day simple moving average sits at $1.19, while the 200-day simple moving average is $1.72. Near-term support is reported at $1.07 and resistance at $1.35.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.05 | $1.18 | $1.48 | 0% | Neutral | |
| $1.10 | $1.39 | $1.85 | +18% | Neutral | |
| $1.22 | $1.59 | $2.19 | +34% | Bullish | |
| $1.31 | $1.73 | $2.47 | +47% | Bullish | |
| $1.39 | $1.88 | $2.75 | +59% | Bullish | |
| $1.34 | $1.85 | $2.76 | +57% | Bullish | |
| $1.37 | $1.93 | $2.94 | +64% | Bullish | |
| $1.38 | $1.98 | $3.06 | +67% | Bullish | |
| $1.42 | $2.06 | $3.24 | +75% | Bullish | |
| $1.81 | $2.67 | $4.27 | +127% | Bullish | |
| $1.90 | $3.01 | $5.12 | +155% | Bullish | |
| $3.72 | $6.62 | $12.34 | +461% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.05 | $1.18 | $1.37 | +0.00% |
| August 2026 | $0.9804 | $1.16 | $1.41 | -1.86% |
| September 2026 | $0.9768 | $1.16 | $1.43 | +0.35% |
| October 2026 | $0.936 | $1.12 | $1.39 | -3.58% |
| November 2026 | $0.9298 | $1.12 | $1.40 | -0.15% |
| December 2026 | $0.9725 | $1.18 | $1.48 | +5.10% |
Click any year to see its month-by-month INO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The INO price prediction for 2026 points to an average of $1.18 (low $1.05, high $1.48) — a potential gain of 0% on today's $1.18. A consolidation phase looks the most probable path here.
In 2027, INO is projected to trade between $1.10 and $1.85, averaging $1.39 — a potential gain of +18% from today's $1.18. That is up +18% on the projected 2026 average. Price action looks broadly range-bound.
Inovio Pharmaceuticals, Inc.'s 2028 outlook centres on $1.59, within a $1.22 to $2.19 range. That is up +14% on the projected 2027 average. That marks a +34% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, INO could reach as high as $2.47, with a base case around $1.73 and support toward $1.31 — roughly +47% from $1.18. Momentum favours further upside here.
Expect INO to range from $1.39 to $2.75 through 2030. The $1.88 average target implies a +59% move from current prices. That is up +9% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The INO price prediction for 2031 points to an average of $1.85 (low $1.34, high $2.76) — a potential gain of +57% on today's $1.18. Momentum favours further upside here.
In 2032, INO is projected to trade between $1.37 and $2.94, averaging $1.93 — a potential gain of +64% from today's $1.18. That is up +5% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Inovio Pharmaceuticals, Inc.'s 2033 outlook centres on $1.98, within a $1.38 to $3.06 range. That is up +2% on the projected 2032 average. That marks a +67% change versus current levels. Momentum favours further upside here.
By 2034, INO could reach as high as $3.24, with a base case around $2.06 and support toward $1.42 — roughly +75% from $1.18. Buyers look set to stay in control over this stretch.
Expect INO to range from $1.81 to $4.27 through 2035. The $2.67 average target implies a +127% move from current prices. That is up +30% on the projected 2034 average. Momentum favours further upside here.
The INO price prediction for 2040 points to an average of $3.01 (low $1.90, high $5.12) — a potential gain of +155% on today's $1.18. Buyers look set to stay in control over this stretch.
In 2050, INO is projected to trade between $3.72 and $12.34, averaging $6.62 — a potential gain of +461% from today's $1.18. That is up +120% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in INO today (≈ 847.457627 INO) could be worth
$5,609.99
+$4,609.99 (+461%) by 2050 · US Dollar
Based on the average projected INO price of $6.62 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in INOwould be worth at today's price.
$1,000 invested in INO on Jul 10, 2025 (≈ 719.424468 INO) would be worth
$848.92
-$151.08 (-15.1%) today · 0.85× · US Dollar
Based on a INO entry price of $1.39 vs. today's $1.18.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.22 | $967.21 | -3.3% |
| 1 month ago | $1.09 | $1,082.57 | +8.3% |
| 3 months ago | $1.06 | $1,113.21 | +11.3% |
| 6 months ago | $1.54 | $766.23 | -23.4% |
| 1 year ago | $1.39 | $848.92 | -15.1% |
| All time (5.0y) ago | $97.92 | $12.05 | -98.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our INO forecast.
Our base-case forecast reaches $2.40 around 2035.
Implied market cap at $2.40: $197.46M
The multi-year forecast shows a rising average price from 2026 onward, with 2026 at an average of $1.19 and 2050 at $7.11. The trajectory carries a bullish tilt from 2028 through 2050, with the forecasted average price climbing to $1.94 by 2030 and to $3.16 by 2040, then to $7.11 in 2050. The implied returns rise from 0% in 2026 to 62.8% by 2030, 165.5% by 2040, and 497.5% by 2050, reflecting substantial upside as the years progress.
These are estimates, not guarantees, and should be weighed with the inherent uncertainty of biotech equities and market conditions.
Tap a question to reveal the answer.
The forecast shows min $1.41, avg $1.94, max $2.87 with an ROI of 62.8%.
Forecasts indicate a bullish trajectory from 2028 onward with rising averages and an ROI that reaches 62.8% by 2030 and 497.5% by 2050. These are estimates, not guarantees.
Yes—2040 max is $5.48 and 2040 average is $3.16, with 2050 max reaching $13.55. This suggests a possible path to $5 around 2040 under the forecast.
Current price is $1.19 and market cap is $97.91M.
30-day range: low $0.9794 and high $1.45.
Inovio Pharmaceuticals, Inc. Community Discussion
0Share your Inovio Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.